Could a malaria drug help fight liver cancer?
NCT ID NCT03037437
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether adding hydroxychloroquine (a malaria drug) to the standard cancer drug sorafenib could slow tumor growth in people with advanced liver cancer. 64 adults who were not candidates for surgery or transplant took part. The goal was to see if the combination delayed cancer progression better than sorafenib alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sorafenib and hydroxychloroquine
What this could lead to
If successful, this combination could slow liver cancer growth better than sorafenib alone, offering a new treatment option for advanced cases.
What could go wrong
This is a small, early-phase trial (64 people) with no control group for comparison. The combination may not improve outcomes and could cause additional side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas Health Cancer Center
San Antonio, Texas, 78229, United States